Pain being trained on Riva!!!

Discussion in 'Ortho-McNeil' started by Anonymous, Mar 10, 2011 at 8:22 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Pain is being trained on Riva! Seeding the orthopedic market. What does that saw about AI/GI?
     

  2. Anonymous

    Anonymous Guest

    Nothing... we've bailed out your asses on Nucynta, we'll do it again.
     
  3. Anonymous

    Anonymous Guest

    J&J loves specialty sales forces and most of the new products fit in that area. AI/GI has contract sales reps. Could be that primary care is going to contract sales reps!
     
  4. Anonymous

    Anonymous Guest

    That is so NOT true. AIGI has made very LITTLE difference to the Nucynta bottom line
     
  5. Anonymous

    Anonymous Guest

    Very true. Nucynta is still a dog!
     
  6. Anonymous

    Anonymous Guest

    There will be no training on anything until the end of respiratory season. Then and only then the new training will begin. However, it will be with a new company once you find employment.

    Riva is again delayed folks, wake up.
     
  7. Anonymous

    Anonymous Guest

    Just amazing how NOBODY gets it!
     
  8. Anonymous

    Anonymous Guest

    Does not mean shit? If you listened you know they call on OS so they are being trained now AIGI for later indications. Just do your job and AIGI was a primary contributor to Nucynta's success.
     
  9. Anonymous

    Anonymous Guest

    Nucynta's success? Are you out of your head?
     
  10. Anonymous

    Anonymous Guest

    Most of my AIGI friends missed Pres Circle due to their horrific Nucynta no.s
     
  11. Anonymous

    Anonymous Guest

    Is it really delayed? How long?
     
  12. Anonymous

    Anonymous Guest

    Year end at best. Maybe 2012. Ask your RBD, nah, scratch that last one, they're all on LinkedIn updating their contacts for near-future reference.
     
  13. Anonymous

    Anonymous Guest

    I looked on line to see if I could find any notifications from the FDA about a delay and couldn't find anything. Has anyone been officially notified from any source? I really wanted to sell this one. Just curious also if you know the reason sited for the delay.
     
  14. Anonymous

    Anonymous Guest

    Ask the brand team.
     
  15. Anonymous

    Anonymous Guest

    and some of us won BECAUSE of our nucynta numbers! ai/gi can't sell in a generic mkt, sorry
     
  16. Anonymous

    Anonymous Guest

    Plus it's tough to convince FP/IM to Rx Ciis.
     
  17. Anonymous

    Anonymous Guest




    I know, as if this would be shocking news...Hey, instead of hiring hundreds only to lay them off later why not train a sales force that already works for J&J !!! Genius!!! cant belive someone thought to do this....amazing

    Boy... someone's earned an encore award
     
  18. Anonymous

    Anonymous Guest

    You will be retrained on Xarelto a couple more times before the green light, seen it, done it with other J&J products.
     
  19. Anonymous

    Anonymous Guest

    Home Office

    It is just a matter of time. The decision have been made. It came down to profits. Profits are winding down from Leva, and Aci how small they are but the profits are starting for Nucynta. there is one problem with Nucynta that is ER there is yet another delay. The IR is not brining in profits yet and they will not keep 1750 people selling it forever.

    Bottom line without any AI/GI medication there is not AI/GI sales team. There will be no Pain specialty division and all this will be finalized and rolled out with in the next 30 days! There will be a combination and they will be selling Rivo,Nucy,ACI,Remi and they will be called Retail sales team. The bad news is there will not be 940 which is the rough count now, they have not finalized the numbers yet they are still waiting to see exact dates on Rivo's FM indication and NucER time line.
     
  20. Anonymous

    Anonymous Guest

    That all makes perfect sense except the 30 day timeline. End of the quarter (June) would make more sense. Perhaps you mean the changes will be rolled out to upper management, then mid-management, then the field. Your post suggests a possible head-count reduction or does it suggest an expansion??? Do you know if pods are back on the table? Thanks for what seems like an accurate or at least honest post.